Related Experiment Video
Updated: Jul 2, 2026
06:16
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
A model for decision support in signal triage.
Bennett Levitan1, Chuen L Yee, Leo Russo
1Pharmaceutical Portfolio & Decision Analysis, Johnson & Johnson Pharmaceutical Services, Titusville, New Jersey, USA.
Drug Safety
|August 19, 2008
Summary
This study introduces a decision analysis model to prioritize important drug-adverse event signals from spontaneous reporting databases. The model aims to improve the efficiency of pharmacovigilance signal triage.
Area of Science:
- Pharmacovigilance
- Drug Safety
- Regulatory Science
Background:
- Spontaneous reporting is crucial for pharmacovigilance.
- Statistical tools generate numerous drug-adverse drug reaction (ADR) signals.
- Prioritizing medically important signals for investigation is challenging.
Purpose of the Study:
- To develop a systematic approach for prioritizing drug-ADR signals.
- To identify and quantify factors influencing signal triage decisions.
- To create a model for ranking signals from quantitative methods.
Main Methods:
- Applied decision analysis to assess attributes of spontaneously reported ADRs.
- Developed a model integrating these assessments.
- Used quantitative signaling methods to generate signals.
Main Results:
- Preliminary results indicate the model can rank drug-ADR combinations for further review.
- The approach systematically assesses signal attributes.
- Formal decision analysis shows potential benefits for signal triage.
Conclusions:
- A formal decision analysis model can aid in prioritizing drug-ADR signals.
- This approach addresses the need for objective signal triage in pharmacovigilance.
- Further research is needed to fully evaluate the model's performance.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:14Decision Making: Traditional Method
The process of hypothesis testing based on the traditional method includes calculating the critical value, testing the value of the test statistic using the sample data, and interpreting these values.
First, a specific claim about the population parameter is decided based on the research question and is stated in a simple form. Further, an opposing statement to this claim is also stated. These statements can act as null and alternative hypotheses, out of which a null hypothesis would be a...
First, a specific claim about the population parameter is decided based on the research question and is stated in a simple form. Further, an opposing statement to this claim is also stated. These statements can act as null and alternative hypotheses, out of which a null hypothesis would be a...